Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data

(2012) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

(2011) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

Influence of Mineral Water on Absorption of Oral Alendronate in Rats

(2011) Yuuki AKAGI et al.   YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN

Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females

(2010) Robert R. Recker et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Vertebral fracture assessment using a semiquantitative technique

(2010) Harry K. Genant et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies

(2010) Ian R Reid et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis

(2009) D. L. Kendler et al.   OSTEOPOROSIS INTERNATIONAL

Effectiveness of bisphosphonate therapy in a community setting

(2008) Adrianne C. Feldstein et al.   BONE